KIFC1

KIFC1, also known as kinesin family member C1, is a protein that in humans is encoded by the KIFC1 gene. This protein is part of the kinesin superfamily, a diverse group of microtubule-based motor proteins that play important roles in intracellular transport and cell division. Specifically, KIFC1 is involved in the minus-end-directed transport of various cargoes, including vesicles, organelles, and macromolecules, towards the cell center in a process critical for mitosis and meiosis.

Function[edit | edit source]

KIFC1 is a motor protein that moves along microtubules, which are part of the cell's cytoskeleton. Unlike most kinesin proteins that move towards the plus end of microtubules, KIFC1 moves towards the minus end, towards the center of the cell. This movement is essential for the proper segregation of chromosomes during cell division, especially during the formation of the mitotic spindle in mitosis and the movement of chromosomes during meiosis. KIFC1 has also been implicated in the transport of mRNA particles and organelles within neurons, indicating a role in neuronal function and development.

Clinical Significance[edit | edit source]

Alterations in the expression or function of KIFC1 have been associated with various cancers, including breast cancer, ovarian cancer, and prostate cancer. Overexpression of KIFC1 has been observed in tumor cells and is thought to contribute to aneuploidy and chromosomal instability, key features of cancer cells. Consequently, KIFC1 is being studied as a potential target for cancer therapy, with the aim of developing drugs that can inhibit its function and thus prevent the proliferation of cancer cells.

Research[edit | edit source]

Research on KIFC1 has focused on understanding its role in cell division and its potential as a target for cancer therapy. Studies have explored the mechanism by which KIFC1 contributes to the proper segregation of chromosomes and how its dysfunction can lead to chromosomal instability. Additionally, efforts are being made to identify inhibitors of KIFC1 that could be used to treat cancers characterized by its overexpression.